Psoriatic Arthritis Pipeline 2026: Drugs in Trials & Targets

Remission & chronicity

Spontaneous remission

Spontaneous remission uncommon (<5%); progressive joint damage in 40-60% without adequate treatment; enthesitis, dactylitis, axial involvement accumulate over time

Best-intervention remission

IL-17 inhibitors: ACR50 response 58-62%, MDA (minimal disease activity) in 40-50%; IL-23 inhibitors (guselkumab, risankizumab): similar efficacy with better skin clearance; JAK inhibitors (upadacitinib): ACR50 71% at 26 weeks; drug-free remission in ~15% in early PsA with T2T

Gap size

Large — most patients are undertreated on methotrexate or NSAIDs alone; treat-to-target poorly implemented

Primary barrier

practice/access

Diagnostic delay (mean 5-7 years from symptom onset to PsA diagnosis); methotrexate has modest efficacy in PsA but is gatekept as mandatory step before biologic access in many health systems; treat-to-target (MDA as goal) poorly implemented; most patients cycle through multiple NSAIDs before biologic access

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CTLA4 32 IL17A 72 IL23A 8 IL23R 178 JAK1 189 PDE4D 184 TNF 277

CTLA4

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
TREMELIMUMAB	↓ inhibits	Mechanistic		DGIdb
IPILIMUMAB	↓ inhibits	Mechanistic		DGIdb
CYCLOSPORINE	? unclear	Mechanistic		DGIdb
ATEZOLIZUMAB	? unclear	Mechanistic		DGIdb
VISILIZUMAB	? unclear	Mechanistic		DGIdb
BLEOMYCIN	? unclear	Mechanistic		DGIdb
ANTIBIOTIC	? unclear	Mechanistic		DGIdb
METHIMAZOLE	? unclear	Mechanistic		DGIdb
RETRO-INVERSO PEPTIDE	? unclear	Mechanistic		DGIdb
MELPHALAN	? unclear	Mechanistic		DGIdb
RECOMBINANT FAS LIGAND	? unclear	Mechanistic		DGIdb
ZALIFRELIMAB	↓ inhibits	Mechanistic		DGIdb
RIBAVIRIN	? unclear	Mechanistic		DGIdb
ANTI-THYMOCYTE GLOBULIN	? unclear	Mechanistic		DGIdb
QUAVONLIMAB	↓ inhibits	Mechanistic		DGIdb
COMPOUND 32 [PMID: 20471253]	↓ inhibits	Mechanistic		DGIdb
SIROLIMUS	? unclear	Mechanistic		DGIdb
BISPECIFIC ANTIBODY	? unclear	Mechanistic		DGIdb
CADONILIMAB	↓ inhibits	Mechanistic		DGIdb
APLITHIANINE A	↓ inhibits	Mechanistic		DGIdb
PEGINTERFERON ALFA-2A	? unclear	Mechanistic		DGIdb
INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE INHIBITOR FF-10501-01	? unclear	Mechanistic		DGIdb
ABATACEPT	? unclear	Mechanistic		DGIdb
WORTMANNIN	? unclear	Mechanistic		DGIdb
ERFONRILIMAB	↓ inhibits	Mechanistic		DGIdb
THALIDOMIDE	? unclear	Mechanistic		DGIdb
FF-10501-01	? unclear	Mechanistic		DGIdb
PEGINTERFERON ALFA-2B	? unclear	Mechanistic		DGIdb
TETRADECANOYLPHORBOL ACETATE	? unclear	Mechanistic		DGIdb
DEHYDRATED ALCOHOL	? unclear	Mechanistic		DGIdb
PREDNISONE	? unclear	Mechanistic		DGIdb
CHEMBL5291170	↓ inhibits	Mechanistic	31000.0 nM (Kd)	ChEMBL

IL17A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
SIMVASTATIN	? unclear	Mechanistic		DGIdb
IL-12	? unclear	Mechanistic		DGIdb
SECUKINUMAB	↓ inhibits	Mechanistic		DGIdb
TIBULIZUMAB	↓ inhibits	Mechanistic		DGIdb
BIMEKIZUMAB	↓ inhibits	Mechanistic		DGIdb
ANTI-IL17A MONOCLONAL ANTIBODY CJM112	? unclear	Mechanistic		DGIdb
VUNAKIZUMAB	↓ inhibits	Mechanistic		DGIdb
M-1095	↓ inhibits	Mechanistic		DGIdb
AFASEVIKUMAB	↓ inhibits	Mechanistic		DGIdb
PERAKIZUMAB	↓ inhibits	Mechanistic		DGIdb
SIROLIMUS	? unclear	Mechanistic		DGIdb
GENTAMICIN	? unclear	Mechanistic		DGIdb
AZATHIOPRINE	? unclear	Mechanistic		DGIdb
VIDOFLUDIMUS	? unclear	Mechanistic		DGIdb
COVA322	? unclear	Mechanistic		DGIdb
BRODALUMAB	? unclear	Mechanistic		DGIdb
IXEKIZUMAB	↓ inhibits	Mechanistic		DGIdb
IZOKIBEP	↓ inhibits	Mechanistic		DGIdb
REMTOLUMAB	? unclear	Mechanistic		DGIdb
TETRACYCLINE	? unclear	Mechanistic		DGIdb
ERYTHROMYCIN	? unclear	Mechanistic		DGIdb
MANNITOL	? unclear	Mechanistic		DGIdb
ABBV-257	? unclear	Mechanistic		DGIdb
CJM-112	~ modulates	Mechanistic		DGIdb
CHEMBL4872876	↓ inhibits	Mechanistic	110.0 nM (Kd)	ChEMBL
CHEMBL4858175	↓ inhibits	Mechanistic	12.3 nM (Kd)	ChEMBL
CHEMBL4854787	↓ inhibits	Mechanistic	89.0 nM (Kd)	ChEMBL
CHEMBL4878993	↓ inhibits	Mechanistic	12.9 nM (Kd)	ChEMBL
CHEMBL4869568	↓ inhibits	Mechanistic	6.2 nM (Kd)	ChEMBL
CHEMBL4876088	↓ inhibits	Mechanistic	10.1 nM (IC50)	ChEMBL
CHEMBL4860250	↓ inhibits	Mechanistic	14.3 nM (IC50)	ChEMBL
CHEMBL4866932	↓ inhibits	Mechanistic	10.1 nM (IC50)	ChEMBL
CHEMBL4874078	↓ inhibits	Mechanistic	7.0 nM (IC50)	ChEMBL
CHEMBL4845695	↓ inhibits	Mechanistic	2.8 nM (IC50)	ChEMBL
CHEMBL4855085	↓ inhibits	Mechanistic	4.6 nM (IC50)	ChEMBL
CHEMBL4860574	↓ inhibits	Mechanistic	2.0 nM (IC50)	ChEMBL
CHEMBL4865978	↓ inhibits	Mechanistic	2.0 nM (IC50)	ChEMBL
CHEMBL4870813	↓ inhibits	Mechanistic	1.0 nM (IC50)	ChEMBL
CHEMBL4850368	↓ inhibits	Mechanistic	3.0 nM (IC50)	ChEMBL
CHEMBL4851738	↓ inhibits	Mechanistic	3.0 nM (IC50)	ChEMBL

Showing top 40 of 72 agents ranked by evidence tier.

IL23A

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Source
USTEKINUMAB	↓ inhibits	Mechanistic	DGIdb
RISANKIZUMAB	↓ inhibits	Mechanistic	DGIdb
MIRIKIZUMAB	↓ inhibits	Mechanistic	DGIdb
BRAZIKUMAB	↓ inhibits	Mechanistic	DGIdb
TILDRAKIZUMAB	↓ inhibits	Mechanistic	DGIdb
GUSELKUMAB	↓ inhibits	Mechanistic	DGIdb
EBDAROKIMAB	↓ inhibits	Mechanistic	DGIdb
BRIAKINUMAB	↓ inhibits	Mechanistic	DGIdb

IL23R

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
INFLIXIMAB	? unclear	Mechanistic		DGIdb
AZATHIOPRINE	? unclear	Mechanistic		DGIdb
CELECOXIB	? unclear	Mechanistic		DGIdb
CHEMBL4206167	↓ inhibits	Mechanistic	1.81 nM (Kd)	ChEMBL
CHEMBL4567228	↓ inhibits	Mechanistic	113.0 nM (IC50)	ChEMBL
CHEMBL4555885	↓ inhibits	Mechanistic	32.0 nM (IC50)	ChEMBL
CHEMBL4529484	↓ inhibits	Mechanistic	25.0 nM (IC50)	ChEMBL
CHEMBL4577218	↓ inhibits	Mechanistic	39.0 nM (IC50)	ChEMBL
CHEMBL4442232	↓ inhibits	Mechanistic	892.0 nM (IC50)	ChEMBL
CHEMBL4565015	↓ inhibits	Mechanistic	37.0 nM (IC50)	ChEMBL
CHEMBL4515769	↓ inhibits	Mechanistic	199.0 nM (IC50)	ChEMBL
CHEMBL4451305	↓ inhibits	Mechanistic	79.0 nM (IC50)	ChEMBL
CHEMBL4441983	↓ inhibits	Mechanistic	220.0 nM (IC50)	ChEMBL
CHEMBL4537768	↓ inhibits	Mechanistic	102.0 nM (IC50)	ChEMBL
CHEMBL4458363	↓ inhibits	Mechanistic	78.0 nM (IC50)	ChEMBL
CHEMBL4454287	↓ inhibits	Mechanistic	183.0 nM (IC50)	ChEMBL
CHEMBL4452903	↓ inhibits	Mechanistic	57.0 nM (IC50)	ChEMBL
CHEMBL4457621	↓ inhibits	Mechanistic	52.0 nM (IC50)	ChEMBL
CHEMBL4543753	↓ inhibits	Mechanistic	518.0 nM (IC50)	ChEMBL
CHEMBL4527549	↓ inhibits	Mechanistic	153.0 nM (IC50)	ChEMBL
CHEMBL4540496	↓ inhibits	Mechanistic	223.0 nM (IC50)	ChEMBL
CHEMBL4524632	↓ inhibits	Mechanistic	79.0 nM (IC50)	ChEMBL
CHEMBL4459265	↓ inhibits	Mechanistic	124.0 nM (IC50)	ChEMBL
CHEMBL4550853	↓ inhibits	Mechanistic	2584.0 nM (IC50)	ChEMBL
CHEMBL4435141	↓ inhibits	Mechanistic	30000.0 nM (IC50)	ChEMBL
CHEMBL4446365	↓ inhibits	Mechanistic	100.0 nM (IC50)	ChEMBL
CHEMBL4462185	↓ inhibits	Mechanistic	96.0 nM (IC50)	ChEMBL
CHEMBL4454702	↓ inhibits	Mechanistic	99.0 nM (IC50)	ChEMBL
CHEMBL4576008	↓ inhibits	Mechanistic	95.0 nM (IC50)	ChEMBL
CHEMBL4589681	↓ inhibits	Mechanistic	107.0 nM (IC50)	ChEMBL
CHEMBL4583420	↓ inhibits	Mechanistic	101.0 nM (IC50)	ChEMBL
CHEMBL4440544	↓ inhibits	Mechanistic	107.0 nM (IC50)	ChEMBL
CHEMBL4564118	↓ inhibits	Mechanistic	47.0 nM (IC50)	ChEMBL
CHEMBL4537038	↓ inhibits	Mechanistic	59.0 nM (IC50)	ChEMBL
CHEMBL4547985	↓ inhibits	Mechanistic	206.0 nM (IC50)	ChEMBL
CHEMBL4558328	↓ inhibits	Mechanistic	40.0 nM (IC50)	ChEMBL
CHEMBL4567670	↓ inhibits	Mechanistic	139.0 nM (IC50)	ChEMBL
CHEMBL4582731	↓ inhibits	Mechanistic	1885.0 nM (IC50)	ChEMBL
CHEMBL4435308	↓ inhibits	Mechanistic	134.0 nM (IC50)	ChEMBL
CHEMBL4564607	↓ inhibits	Mechanistic	48.0 nM (IC50)	ChEMBL

Showing top 40 of 178 agents ranked by evidence tier.

JAK1

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
RUXOLITINIB	↓ inhibits	Mechanistic	3.0 nM (IC50)	DGIdb
IZENCITINIB	↓ inhibits	Mechanistic		DGIdb
PEMBROLIZUMAB	? unclear	Mechanistic		DGIdb
RUXOLITINIB PHOSPHATE	↓ inhibits	Mechanistic		DGIdb
GOLIDOCITINIB	↓ inhibits	Mechanistic		DGIdb
FILGOTINIB MALEATE	↓ inhibits	Mechanistic		DGIdb
MOMELOTINIB	↓ inhibits	Mechanistic	11.0 nM (IC50)	DGIdb
AZD1480	↓ inhibits	Mechanistic		DGIdb
DELGOCITINIB	↓ inhibits	Mechanistic		DGIdb
TRICETAMIDE	↓ inhibits	Mechanistic		DGIdb
TOFACITINIB	↓ inhibits	Mechanistic	112.0 nM (IC50)	DGIdb
PEFICITINIB	↓ inhibits	Mechanistic		DGIdb
BREPOCITINIB	↓ inhibits	Mechanistic		DGIdb
UPADACITINIB HEMIHYDRATE	↓ inhibits	Mechanistic		DGIdb
CYCLOSPORINE	? unclear	Mechanistic		DGIdb
INCB-047986	↓ inhibits	Mechanistic		DGIdb
ABROCITINIB	↓ inhibits	Mechanistic		DGIdb
ENZASTAURIN	? unclear	Mechanistic		DGIdb
CERDULATINIB	↓ inhibits	Mechanistic		DGIdb
NEZULCITINIB	↓ inhibits	Mechanistic		DGIdb
FILGOTINIB	↓ inhibits	Mechanistic		DGIdb
GLPG-0555	↓ inhibits	Mechanistic		DGIdb
SOLCITINIB	↓ inhibits	Mechanistic		DGIdb
GUSACITINIB	↓ inhibits	Mechanistic		DGIdb
ITACITINIB	↓ inhibits	Mechanistic		DGIdb
BARICITINIB	↓ inhibits	Mechanistic		DGIdb
MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE	? unclear	Mechanistic		Open Targets
DEURUXOLITINIB PHOSPHATE	? unclear	Mechanistic		Open Targets
TOFACITINIB CITRATE	? unclear	Mechanistic		Open Targets
UPADACITINIB	? unclear	Mechanistic		Open Targets
CHEMBL538798	↓ inhibits	Mechanistic	39810.72 nM (IC50)	ChEMBL
CHEMBL154580	↓ inhibits	Mechanistic	19952.62 nM (IC50)	ChEMBL
SUNITINIB	↓ inhibits	Mechanistic	9.2 nM (Kd)	ChEMBL
CHEMBL386637	↓ inhibits	Mechanistic	1300.0 nM (IC50)	ChEMBL
CHEMBL21156	↓ inhibits	Mechanistic	15.0 nM (IC50)	ChEMBL
CHEMBL56543	↓ inhibits	Mechanistic	3380.0 nM (IC50)	ChEMBL
DOVITINIB	↓ inhibits	Mechanistic	380.0 nM (Kd)	ChEMBL
JNJ-7706621	↓ inhibits	Mechanistic	21.0 nM (Kd)	ChEMBL
SU-014813	↓ inhibits	Mechanistic	97.0 nM (Kd)	ChEMBL
SOTRASTAURIN	↓ inhibits	Mechanistic	7300.0 nM (IC50)	ChEMBL

Showing top 40 of 189 agents ranked by evidence tier.

PDE4D

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
CILOMILAST	↓ inhibits	Mechanistic	63.0 nM (IC50)	DGIdb
TRANIMILAST	↓ inhibits	Mechanistic		DGIdb
RESVERATROL	? unclear	Mechanistic		DGIdb
DIFAMILAST	↓ inhibits	Mechanistic		DGIdb
MK-0873	↓ inhibits	Mechanistic		DGIdb
REVAMILAST	↓ inhibits	Mechanistic		DGIdb
THEOPHYLLINE	↓ inhibits	Mechanistic		DGIdb
DYPHYLLINE	↓ inhibits	Mechanistic		DGIdb
IBUDILAST	↓ inhibits	Mechanistic		DGIdb
HT-0712	↓ inhibits	Mechanistic		DGIdb
ENSIFENTRINE	↓ inhibits	Mechanistic		DGIdb
LIRIMILAST	? unclear	Mechanistic		DGIdb
OXTRIPHYLLINE	↓ inhibits	Mechanistic		DGIdb
DROTAVERIN	↓ inhibits	Mechanistic		DGIdb
TOFIMILAST	↓ inhibits	Mechanistic		DGIdb
THEOPHYLLINE SODIUM GLYCINATE	↓ inhibits	Mechanistic		DGIdb
DIPYRIDAMOLE	↓ inhibits	Mechanistic		DGIdb
GSK-356278	? unclear	Mechanistic		DGIdb
APREMILAST	↓ inhibits	Mechanistic		DGIdb
ETAZOLATE	? unclear	Mechanistic		DGIdb
OGLEMILAST	↓ inhibits	Mechanistic		DGIdb
ZATOLMILAST	↓ inhibits	Mechanistic		DGIdb
TETOMILAST	↓ inhibits	Mechanistic		DGIdb
ROLIPRAM	↓ inhibits	Mechanistic	390.0 nM (IC50)	DGIdb
DENBUFYLLINE	? unclear	Mechanistic		DGIdb
LOTAMILAST	↓ inhibits	Mechanistic		DGIdb
PENTOXIFYLLINE	↓ inhibits	Mechanistic		DGIdb
AMLEXANOX	↓ inhibits	Mechanistic		DGIdb
AMINOPHYLLINE	↓ inhibits	Mechanistic		DGIdb
CRISABOROLE	↓ inhibits	Mechanistic		DGIdb
ROFLUMILAST	↓ inhibits	Mechanistic		DGIdb
PICLAMILAST	? unclear	Mechanistic	0.8 nM (IC50)	DGIdb
PAPAVERINE	? unclear	Mechanistic		DGIdb
GSK-256066	↓ inhibits	Mechanistic		DGIdb
DIURETIC	? unclear	Mechanistic		DGIdb
BPN14770	? unclear	Mechanistic		DGIdb
FLAVOXATE HYDROCHLORIDE	↓ inhibits	Mechanistic		DGIdb
SELECTIVE CYTOKINE INHIBITORY DRUG CC-1088	? unclear	Mechanistic		DGIdb
DOVRAMILAST	↓ inhibits	Mechanistic		DGIdb
QUETIAPINE FUMARATE	? unclear	Mechanistic		DGIdb

Showing top 40 of 184 agents ranked by evidence tier.

TNF

UniProt Ensembl DGIdb Open Targets

Therapeutic Agent	Effect Direction	Evidence Tier	Potency	Source
NERELIMOMAB	↓ inhibits	Mechanistic		DGIdb
CROMOLYN SODIUM	? unclear	Mechanistic		DGIdb
PLACULUMAB	↓ inhibits	Mechanistic		DGIdb
METHYLENE BLUE	? unclear	Mechanistic		DGIdb
ALTEPLASE	? unclear	Mechanistic		DGIdb
CARBOPLATIN	? unclear	Mechanistic		DGIdb
GENTAMICIN	? unclear	Mechanistic		DGIdb
GOLIMUMAB	↓ inhibits	Mechanistic		DGIdb
BUPIVACAINE	? unclear	Mechanistic		DGIdb
PENTOXIFYLLINE	? unclear	Mechanistic	85000.0 nM (IC50)	DGIdb
BENZO[E]PYRENE	? unclear	Mechanistic		DGIdb
THALIDOMIDE	? unclear	Mechanistic		DGIdb
PYRAZINAMIDE	? unclear	Mechanistic		DGIdb
GLIMEPIRIDE	? unclear	Mechanistic		DGIdb
OMEPRAZOLE	? unclear	Mechanistic		DGIdb
LENERCEPT	↓ inhibits	Mechanistic		DGIdb
ADALIMUMAB	↓ inhibits	Mechanistic		DGIdb
PRAZOSIN HYDROCHLORIDE	? unclear	Mechanistic		DGIdb
REMTOLUMAB	? unclear	Mechanistic		DGIdb
MIDOSTAURIN	? unclear	Mechanistic		DGIdb
LENABASUM	? unclear	Mechanistic		DGIdb
MAGNESIUM SULFATE ANHYDROUS	? unclear	Mechanistic		DGIdb
PICIBANIL	? unclear	Mechanistic		DGIdb
FLUOCINOLONE ACETONIDE	? unclear	Mechanistic		DGIdb
MILTEFOSINE	? unclear	Mechanistic		DGIdb
HOMIDIUM BROMIDE	? unclear	Mechanistic		DGIdb
OZORALIZUMAB	↓ inhibits	Mechanistic		DGIdb
PEGSUNERCEPT	↓ inhibits	Mechanistic		DGIdb
CERTOLIZUMAB PEGOL	↓ inhibits	Mechanistic		DGIdb
THERAPEUTIC HORMONE	? unclear	Mechanistic		DGIdb
NAFAMOSTAT	? unclear	Mechanistic		DGIdb
FOLIC ACID	? unclear	Mechanistic		DGIdb
ABBV-257	? unclear	Mechanistic		DGIdb
RISPERIDONE	? unclear	Mechanistic		DGIdb
COVA322	? unclear	Mechanistic		DGIdb
HYDROXYCHLOROQUINE	? unclear	Mechanistic		DGIdb
CERTOLIZUMAB	? unclear	Mechanistic		DGIdb
AN0128	? unclear	Mechanistic		DGIdb
5,7-DIHYDROXY-4-METHYLCOUMARIN	? unclear	Mechanistic		DGIdb
SORAFENIB	? unclear	Mechanistic		DGIdb

Showing top 40 of 277 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Psoriatic Arthritis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Active Not Recruiting

NCT03671148 Phase: 3 Started: 2019-03-07

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) Active Not Recruiting

NCT07486960 Phase: 2 Started: 2026-04-20

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA....

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis Recruiting

NCT04804553 Phase: 3 Started: 2022-03-17

The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Active Not Recruiting

NCT04908202 Phase: 3 Started: 2021-07-13

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety in...

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

NCT06671483 Phase: 3 Started: 2025-03-03

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modify...

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines Active Not Recruiting

NCT06671496 Phase: 3 Started: 2025-03-10

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA based on their previous experience with specific treatments. The ...

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). Recruiting

NCT06751238 Phase: 1 Started: 2025-09-24

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis Recruiting

NCT07801495 Phase: 2 Started: 2026-10-14

The purpose of this Phase 2a/b study is: 1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). 2. to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis Recruiting

NCT06869551 Phase: 3 Started: 2025-03-13

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed

NCT03895203 Phase: 3 Started: 2019-04-03

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed

NCT03896581 Phase: 3 Started: 2019-03-28

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthritis (PsA).

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) Active Not Recruiting

NCT06864026 Phase: 4 Started: 2025-03-06

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment Active Not Recruiting

NCT04908189 Phase: 3 Started: 2021-07-15

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will...

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Recruiting

NCT07286058 Phase: 3 Started: 2026-03-11

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) tre...

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis Completed

NCT04009499 Phase: 3 Started: 2019-08-13

This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).

Agents Found By Disease-Level Search

Searched directly from “Psoriatic Arthritis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

48 agents shown (approved or with trial evidence) — 35 not found by the gene-target search above.

Secukinumab

Approved · 9 trials · source: ClinicalTrials.gov, Open Targets
NCT06751238 NCT02721966 NCT01989468

Adalimumab

Approved · 6 trials · source: ClinicalTrials.gov, Open Targets
NCT03104400 NCT03895203 NCT02745080

MethotrexateNOT in gene-target list

Approved · 5 trials · source: ClinicalTrials.gov, Open Targets
NCT03402087 NCT07086924 NCT01313858

Guselkumab

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT05049798 NCT02103361 NCT04882098

Bimekizumab

Phase 3 · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT03896581 NCT06668181 NCT04009499

Etanercept

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT02376790 NCT00962741 NCT03955861

Risankizumab

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT03675308 NCT04846959 NCT02719171

Ixekizumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02584855 NCT04527380

Ustekinumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03881059 NCT02103361

DeucravacitinibNOT in gene-target list

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT07280702 NCT06869551

Apremilast

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT03828045 NCT02775500

golimumab

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01081717 NCT03955861

ZasocitinibNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT07286058

IL-17iNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05049798

secukinumab (AIN457A)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01169844

CabozantinibNOT in gene-target list